Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsAddiction psychiatry — nicotine and behavioural addictions

Psych MEQs / SAQs · Addiction psychiatry — nicotine and behavioural addictions

Nicotine, varenicline, and dual diagnosis smoking — MEQ

FRANZCP-style MEQ integrating FTND-level dependence, combination NRT/varenicline, EAGLES, clozapine-smoking interaction, and gambling risk/safeguards.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 36-year-old man with schizophrenia (stable on clozapine 400 mg nightly) smokes 30 cigarettes/day, first cigarette within 5 minutes of waking. He has failed three unassisted quit attempts and one patch-only course. He is admitted to a smoke-free ward after a psychotic relapse that has now largely settled. Nursing staff report escalating irritability since admission. He asks whether varenicline will 'make me suicidal' and whether he should 'just detox cold turkey'. Separately, his partner discloses he has been gambling online sports bets and hiding a $40,000 debt; he denies suicidal ideation on brief screen. (i) Interpret nicotine dependence severity and the ward irritability. (ii) Propose a pharmacotherapy and behavioural plan with named agents, doses/titration principles, and monitoring — including clozapine interaction issues. (iii) Address EAGLES-era safety counselling for varenicline in psychiatric illness. (iv) Outline assessment and management priorities for the gambling disclosure. (v) List disposition and harm-reduction steps for discharge. (20 marks)

Model answer

Reveal model answer

(i) Dependence and ward irritability. Thirty cigarettes/day with time to first cigarette ≤5 minutes indicates high nicotine dependence on FTND logic. Abrupt forced abstinence on a smoke-free ward without adequate NRT commonly produces withdrawal (irritability, craving, poor concentration) that can be misread as personality or early relapse — treat nicotine withdrawal actively while monitoring psychosis.[2][4]

(ii) Pharmacotherapy and behavioural plan. Same-day combination NRT: high-dose patch (commonly 21 mg/24 h if appropriate) plus short-acting gum 4 mg or lozenge/spray for breakthrough craving, with behavioural support and quit-date planning if he elects a full quit during admission. Alternatively or sequentially, varenicline titration 0.5 mg daily ×3 days → 0.5 mg BD ×4 days → 1 mg BD, typically start before quit date when ambulatory, course often 12 weeks, with nausea/sleep counselling.[3][6] Clozapine pearl: smoking cessation reduces polycyclic aromatic hydrocarbon induction of CYP1A2 and can raise clozapine levels — monitor levels/side-effects and adjust dose with the treating psychiatrist; NRT does not replace smoke induction the same way. Avoid bupropion if seizure risk is a concern on clozapine (individualise). Offer structured counselling/quitline linkage.[4]

(iii) EAGLES counselling. Explain that EAGLES found no significant increase in the primary composite neuropsychiatric adverse event endpoint for varenicline versus nicotine patch or placebo in smokers with and without psychiatric disorders, while confirming efficacy benefits — so diagnosis of schizophrenia alone is not a reason to withhold. Still monitor mood, psychosis, and suicidality as standard care during any quit attempt.[1]

(iv) Gambling priorities. Take a full gambling history (forms, losses, chasing, concealment, illegal acts), corroborate debt with consent, reassess suicide risk carefully (denial on brief screen is not enough when partner reports catastrophic debt), implement financial safeguards (self-exclusion, third-party money control), offer CBT/MI referral, mutual help, and only consider naltrexone adjunct later under specialist review — not as day-1 sole treatment.[5]

(v) Disposition. Discharge with ongoing NRT or varenicline supply plan, early community follow-up, clozapine monitoring plan if smoking status changes, gambling service referral, partner-inclusive safety plan, crisis contacts, and harm-reduction interim goals if full abstinence not yet secured.[1][4][5]

Common errors

  • Cold turkey on a smoke-free ward without NRT.
  • Refusing varenicline solely because of schizophrenia, ignoring EAGLES.
  • Forgetting clozapine level rise after smoking cessation.
  • Treating gambling as lifestyle advice only without suicide/debt work.
  • Starting naltrexone as first-line without psychosocial/financial plan. [1][5]

Examiner notes

High-scoring answers name combination NRT or varenicline doses, cite EAGLES, mention clozapine/CYP1A2, and structure gambling care around risk + money + CBT, not pharmacology-first. [1][3][5]

References

  1. [1]Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES) Lancet, 2016.PMID 27116918
  2. [2]Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire Br J Addict, 1991.PMID 1932883
  3. [3]Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation Cochrane Database Syst Rev, 2023.PMID 37335995
  4. [4]Tsoi DT, Porwal M, Webster AC Interventions for smoking cessation and reduction in individuals with schizophrenia Cochrane Database Syst Rev, 2013.PMID 23450574
  5. [5]Hodgins DC, Stea JN, Grant JE Gambling disorders Lancet, 2011.PMID 21600645
  6. [6]Gonzales D, Rennard SI, Nides M, et al. Varenicline vs sustained-release bupropion and placebo for smoking cessation JAMA, 2006.PMID 16820546